Helix BioMedix, Inc. (HXBM)

OTCMKTS · Delayed Price · Currency is USD
1.000
-0.700 (-41.18%)
At close: Mar 11, 2026
Market Cap224.71K -98.3%
Revenue (ttm)2.07M +14.6%
Net Income-2.58M
EPS-15.59
Shares Out224.71K
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume201
Average Volume255
Open1.000
Previous Close1.700
Day's Range1.000 - 1.000
52-Week Range1.000 - 6.450
Beta0.52
RSI19.54
Earnings Daten/a

About Helix BioMedix

Helix BioMedix, Inc., a biotechnology company, develops peptide-based therapeutics for dermatology and skin health in the United States. It is developing HB4208 for treatment of the rare disease Xeroderma Pigmentosum; and BIOACTIVE SMARTPEPTIDES, a bioactive peptide ingredient for skin care companies. The company was founded in 1988 and is based in Bothell, Washington. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1988
Employees 8
Stock Exchange OTCMKTS
Ticker Symbol HXBM
Full Company Profile

Financial Performance

In 2011, Helix BioMedix's revenue was $1.89 million, an increase of 122.07% compared to the previous year's $851,683. Losses were -$2.49 million, -67.73% less than in 2010.

Financial Statements